secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2022-11-16T23:59:59+00:00
Accession:  0000950170-22-025228
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen pauses SZN-1326 Phase 1 trial due to liver enzyme elevations; Q3 net loss $13.4M
--------------------------------------------------------------------------------

- Voluntarily paused SZN-1326 Phase 1 SAD trial after grade 3 ALT/AST elevations in 3 subjects; transaminases resolved spontaneously.
- SZN-043 Phase 1 ongoing but with grade 1-2 transaminase elevations; re-evaluating timeline.
- Entered partnership with Boehringer Ingelheim for SZN-413; upfront $12.5M, milestones up to $586.5M plus royalties.
- Q3 2022 cash $78.4M (down from $92.7M in Q2); R&D expense $8.6M, net loss $13.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017022025228/0000950170-22-025228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017022025228/srzn-20221114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-025228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer